Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, ANG Lifesciences India has submitted that the total revenue of the Company in first quarter of Financial Year 2021-22 is Rs 118 crore. The Company has been able to show handsome growth in topline backed by persistent and focused efforts by the management in its goal of maintaining the growth trend going forward. The Company has entered into agreement for the supply of medicine with various state government across India worth Rs 250 crore and more, apart from the P to P business and export business worth Rs 100 crore. Further the Company expects to achieve the total sales of Rs 350 crore approximately in the current Financial Year 2021-22 with a healthy bottom-line.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: